XENE (Xenon Pharmaceuticals) Institutional Ownership: 104.79% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XENE Xenon Pharmaceuticals Inc XENE
25 GF Score
Price $66.98
! 5 Warning Signs
View Full Analysis

What is Xenon Pharmaceuticals Institutional Ownership?

Xenon Pharmaceuticals XENE -1.08% 25 Institutional Ownership is 104.79% as of Jul. 16, 2026. GuruFocus rates XENE with a GF Score™ of 25/100. The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Xenon Pharmaceuticals's institutional ownership is 104.79%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Xenon Pharmaceuticals's Insider Ownership is 0.59%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Xenon Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 99.88%.

Xenon Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Xenon Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenon Pharmaceuticals Institutional Ownership Chart

Xenon Pharmaceuticals Historical Data

The historical data trend for Xenon Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 61.42 61.49 61.67 62.83 62.16 59.93 60.99 60.77 59.04 60.99
XENE
25GF Score
Xenon Pharmaceuticals Inc XENE
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenon Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 104.79% mean?
Xenon Pharmaceuticals (XENE) has a Institutional Ownership of 104.79% as of Jul. 16, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Xenon Pharmaceuticals and its competitors.
Is Xenon Pharmaceuticals' Institutional Ownership too high?
Xenon Pharmaceuticals' current Institutional Ownership is 104.79%. Overall, Xenon Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Xenon Pharmaceuticals' Institutional Ownership compare to DFTX and LEGN?
Xenon Pharmaceuticals' Institutional Ownership of 104.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Xenon Pharmaceuticals and its competitors. Xenon Pharmaceuticals's current Institutional Ownership is 104.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenon Pharmaceuticals stock overvalued right now?
Xenon Pharmaceuticals (XENE) has a current Institutional Ownership of 104.79%. The current Institutional Ownership is 104.79%. Xenon Pharmaceuticals' overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Xenon Pharmaceuticals (XENE), the current Institutional Ownership is 104.79% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xenon Pharmaceuticals Business Description

Other Exchanges XP0:Germany
Address 200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
25GF Score

Get the complete analysis for XENE

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$66.98
Price